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We constructed a sensitive and quantitative assay system to examine human T-cell leukemia virus type I (HTLV-I) envelope
(env) glycoprotein-mediated cell fusion in which T7 RNA polymerase in donor cells coexpressing env glycoproteins activates
a reporter gene in recipient cells upon cell fusion. An efficient expression of HTLV-I env glycoproteins (gp46 and gp21) was
observed in 293T cells transfected with an expression plasmid by both immunoblot and immunofluorescence analyses. The
cells expressing env glycoproteins also exhibited self-fusion. By cocultivating the donor cells with recipient cells transfected
with a reporter plasmid possessing the luciferase gene under the T7 promoter, the expression of luciferase was observed
upon cell fusion. The activation of the luciferase gene was inhibited by either anti-env neutralizing antibody or synthetic
peptide corresponding to env gp21, thus indicating the cell fusion to be specifically mediated by the HTLV-I env glycoproteins
expressed in the donor cells. A broad range of cell lines exhibited susceptibility to HTLV-I env-mediated cell fusion by this
assay. This newly established assay system may thus provide an efficient way both to study the fusion mechanisms mediated
by HTLV-I env glycoproteins and to identify the HTLV-I receptor(s). © 1999 Academic Press
h
n
R
u
f
d
u
c
e
(
a
i
s
(
1
r
f
g
q
l
3
1
a
e
t
4
a
(INTRODUCTION
Human T-cell leukemia virus type I (HTLV-I) is a type C
etrovirus etiologically associated with adult T-cell leu-
emia/lymphoma (ATLL) and chronic inflammatory disor-
ers such as HTLV-I associated myelopathy/tropical
pastic paraparesis (HAM/TSP) and uveitis (Gessain et
l., 1985; Hinuma et al., 1981; Miyoshi et al., 1981; Mo-
hizuki et al., 1992; Osame et al., 1987). HTLV-I primarily
nfects CD4-positive T-cells and many different types of
ells such as CD8-positive T-cells, B-cells, monocyte–
acrophages, endothelial cells, fibroblasts, and epithe-
ial cells. The hosts of HTLV-I include various species
uch as humans, monkeys, rabbits, and rats (Fan et al.,
992; Hoxie et al., 1984; Krichbaum-Stenger et al., 1987;
iyoshi et al., 1981; Poiesz et al., 1980). However, the
xact host range and cellular receptor(s) of HTLV-I re-
ain poorly understood due to the inefficient infectivity of
ell-free HTLV-I to target cells.
HTLV-I envelope (env) glycoproteins are synthesized
s a precursor gp61, which is cleaved into a cell surface
gp46) and a transmembrane (gp21) glycoprotein (Pique
t al., 1992; Seiki et al., 1983), and are considered to play
major role in cell-to-cell transmission. It is thought that
he gp46 serves as a virus attachment protein and the
p21 serves as a fusion protein through its N-terminal
1 To whom correspondence and reprint requests should be ad-
ressed. Fax: 81-92-642-5247. E-mail: nakamura@intmed1.med.kyushu-s.ac.jp.
235ydrophobic domain (Delamarre et al., 1994, 1997; De-
esvre et al., 1995; Pique et al., 1990; Ragheb et al., 1995;
oos et al., 1990; Rosenberg et al., 1997). HTLV-I has
nique properties in which cell-to-cell contact is required
or an efficient infection and syncytium formation is in-
uced by the cocultivation of HTLV-I-positive cells with
ninfected target cells. This syncytium formation is effi-
iently inhibited by monoclonal antibody (mAb) against
nv or synthetic peptides corresponding to amino acids
aa) 197–216 of env gp46 and aa 400–429 of env gp21. As
result, HTLV-I env glycoproteins are considered to be
nvolved in the entry of the virus into target cells and the
ubsequent induction of syncytium formation in vitro
Baba et al., 1993, 1995; Kuroki et al., 1992; Palker et al.,
992; Sagara et al., 1996; Tanaka et al., 1994).
On the other hand, the identification of the HTLV-I
eceptor(s) [ligand(s) of env glycoproteins] is important
or understanding viral tropism, replication, and patho-
enesis. Recently, two different molecules that are re-
uired for HTLV-I-induced syncytium formation were iso-
ated from MOLT-4 cell lysates; one is a trypsin-sensitive
4- to 35-kDa molecule that interacts specifically with aa
97–216 of gp46. This molecule was recently identified
s a 71-kDa heat shock cognate protein (HSC70) (Sagara
t al., 1997, 1998). The other molecule is a trypsin-resis-
ant carbohydrate containing lipids that interacts with aa
00–429 of gp21 (Sagara et al., 1997). Furthermore, an
dhesion molecule, vascular cell adhesion molecule-1
VCAM-1), has also been identified as either an acces-
ory molecule or a potential coreceptor for HTLV-I-in-
0042-6822/99 $30.00
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236 OKUMA ET AL.uced syncytium formation (Hildreth et al., 1997). A novel
lycoprotein of the CXC chemokine family, which may be
nvolved in syncytium formation, has recently been iden-
ified in fetal calf serum (FCS) (Okuma et al., in press).
owever, the molecules on the target cells that interact
ith HTLV-I env gp46 or gp21 have not yet been defini-
ively identified and the molecular mechanisms underly-
ng HTLV-I-induced syncytium formation or membrane
usion remain to be elucidated. Therefore, a sensitive
nd quantitative system for analyzing HTLV-I env-medi-
ted cell fusion is required to analyze the mechanism of
TLV-I infection.
Recently, a sensitive, (semi)quantitative, and rapid sys-
em, reporter gene activation assay, measuring the acti-
ation of a reporter gene upon env glycoprotein-medi-
ted cell fusion was developed by using recombinant
accinia viruses and used for the identification of HIV-I
oreceptors or to perform functional analyses of HTLV-II
nv glycoproteins (Alkhatib et al., 1996; Feng et al., 1996;
i et al., 1996; Nussbaum et al., 1994; Poon and Chen,
998). In the present study, we expressed T7 RNA poly-
erase and HTLV-I env glycoproteins in donor cells by
ransfecting their expression plasmids and examined the
ctivation of a reporter plasmid that was transfected in
arious recipient cell lines after the cocultivation of the
onor cells with the recipient cells. By using this sensi-
ive assay system, the host range of HTLV-I was thus
hown to be greater than that reported so far.
RESULTS
xpression of HTLV-I env glycoproteins
The expression of HTLV-I env glycoproteins in 293T
ells transfected with pCAGHTLV-I env possessing the
TLV-I env gene under CAG promoter was examined by
mmunoblotting (Fig. 1A). At 36–48 h posttransfection,
nv p39 and gp21 were definitely observed in the lysate
f the transfected cells in experiment 1 (Fig. 1A, lane 3),
nd env gp46 and p39 were definitely observed in ex-
eriment 2 (Fig. 1A, lane 4). On the other hand, the
recursor of gp61 was not detected by immunoblotting
sing serum from a HAM patient. p39 detected in the
resent study was considered to be the same nonglyco-
ylated form of gp46 as reported by Arp et al. (1996). At
6 h posttransfection, the expression of gp46 was de-
ected on the surface of the transfected 293T cells by an
ndirect immunofluorescence analysis using serum from
HAM patient (Fig. 1B, b) or mAb LAT-27 against gp46
data not shown). 293T cells expressing the env glyco-
roteins showed self-fusion at 60–72 h posttransfection
Fig. 1C, b), which was observed by staining with Giemsa
olution. This indicated the expressed HTLV-I env glyco-
roteins to be functionally active while the 293T cells
ossessed the putative HTLV-I receptor(s). mTLV-I env glycoprotein-mediated cell fusion
293T cells cotransfected with pCAGHTLV-I env and
CAGT7 possessing the T7 RNA polymerase gene under
he CAG promoter were cocultured with HepG2 cells
otransfected with pT7EMCLuc carrying a firefly lucif-
rase gene under a T7 promoter and pRL-CMV possess-
ng a seapansy luciferase gene under a CMV promoter.
he cell fusion activity was measured at the indicated
imes by luciferase expression. 293T cells transfected
ith pCAGT7 alone were used as a control. As shown in
ig. 2, the maximum level of luciferase activity was de-
ected at 5 h after cocultivation. However, in the 293T
ells transfected with pCAGT7 alone, no luciferase ac-
ivity was detected. Therefore, in the subsequent exper-
ments, the luciferase activity (cell fusion activity) was
easured at 5 h after cocultivation.
nhibition of cell fusion by serum from a HAM patient,
nti-env mAb, and synthetic peptide
To analyze the specificity of HTLV-I env-mediated cell
usion in the present system, we examined the effects of
arious agents that are known to inhibit syncytium for-
FIG. 1. Expression of HTLV-I env glycoproteins by transfection with
CAGHTLV-I env. (A) Immunoblot analyses of HTLV-I-positive MT-2
ells (lane 1), 293T cells transfected with pCAGGS (lane 2), and those
ith pCAGHTLV-I env (lanes 3 and 4) at 36–48 h posttransfection by
sing serum from a HAM patient. The molecular masses are indicated.
B) The surface immunofluorescence analyses of 293T cells trans-
ected with pCAGGS (a) and those with pCAGHTLV-I env (b) at 36 h
osttransfection were performed using serum from a HAM patient. (C)
ell fusion activity of 293T cells expressing HTLV-I env glycoproteins.
93T cells transfected with pCAGGS (a) and those with pCAGHTLV-I
nv (b) were observed after Giemsa staining at 60–72 h posttransfec-
ion. Magnification, 6003.ation. These agents include serum from a HAM patient,
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238 OKUMA ET AL.nti-gp46 neutralizing mAb, LAT-27, and synthetic pep-
ides corresponding to aa 197–208 of gp46 and aa 400–
29 of gp21, which were reported to inhibit HTLV-I-in-
uced syncytium formation (Nagy et al., 1983; Sagara et
l., 1996; Tanaka et al., 1994). These agents were added
o HepG2 cells cotransfected with the receptor plasmids
t various concentrations and cocultured with the 293T
ells coexpressing HTLV-I env and T7 RNA polymerase.
s shown in Fig. 3A, the serum from a HAM patient
nhibited the luciferase activity in a dose-dependent
anner compared with the serum from a healthy donor.
he anti-gp46 mAb, LAT-27, inhibited the luciferase ac-
ivity in a dose-dependent manner more than irrelevant
at IgG, which did not inhibit HTLV-I-induced syncytium
ormation (Fig. 3B). Synthetic peptide corresponding to
a 400–429 of gp21 inhibited the luciferase activity in a
ose-dependent manner more than the peptide corre-
ponding to aa 332–352 of gp21, which did not inhibit
TLV-I-induced syncytium formation (Fig. 3C). The inhi-
ition of luciferase activity by the synthetic peptide cor-
esponding to aa 197–209 of gp46 was weaker than that
y aa 400–429 of gp21 (data not shown). The inhibition of
yncytium formation by aa 197–209 of gp46 was also
eaker than that by aa 400–429 of gp21 (data not
hown). These results indicated that the HTLV-I env gly-
oproteins expressed on the surface of donor cells spe-
ifically induce cell fusion by interaction with the putative
ellular receptor(s) of recipient cells.
nalysis of pharmacological agents that block cell
usion
To further analyze the specificity and the efficiency of
FIG. 2. Time course of cell fusion-dependent reporter gene activa-
ion. The luciferase activity was measured at the indicated times after
he initiation of cocultivation of 293T cells transfected with pCAGHTLV-I
nv and pCAGT7 (Env) or with pCAGT7 alone (Cont), with HepG2 cells
ransfected with the reporter plasmids (pT7EMCLuc and pRL-CMV).harmacological agents in HTLV-I env-mediated cell fu- mion, we examined the effects of polyanionic compounds
n the present reporter gene activation assay. Since
TLV-I-induced syncytium formation is inhibited by sul-
ated polysaccharides, dextran sulfate, and heparin, but
ot by dextran, these polyanionic compounds are con-
idered to block cell-to-cell contact, probably indepen-
ent of any influence by the surface adhesion molecules
Ida et al., 1994). As shown in Fig. 4, dextran sulfate and
eparin inhibited the luciferase activity in a dose-
ependent manner, but dextran did not. This indicates
hat cell-to-cell contact is very important in our assay
ystem and this assay system could thus be utilized to
tudy various fusion-blocking agents.
ell fusion activity in various cell lines
To analyze the presence of the putative HTLV-I recep-
or(s) on various cell lines, we examined the fusion ac-
ivity using cell lines derived from several different spe-
ies as recipient cells (Table 1). In HTLV-I-positive MT-2
nd C91/PL cell lines, no significant activation of lucif-
rase was observed, thus indicating that the expression
f the HTLV-I receptor(s) may be down-regulated in
TLV-I-positive cells. Although a significant fold increase
f luciferase activity was observed in most of the cell
ines examined, no increase in luciferase activity was
bserved in the MDBK (bovine kidney), HuH-7 (human
iver), or FLC4 (human liver) cell lines. Syncytia were
ndetectable when these cell lines were cocultured with
TLV-I-positive ILT8M2 cells. Since the seapansy lucif-
rase activity in MDBK cells was much lower (2118 RLU)
han that in HuH-7 and FLC4 cells (1,387,916 and 458,766
LU, respectively), the low fold increase of luciferase
ctivity is very likely due to the low transfection efficiency
o the MDBK cells of the plasmids. These results indicate
hat the host range of HTLV-I is greater than that previ-
usly reported (Li et al., 1996; Nagy et al., 1983; Sommer-
elt et al., 1988) and that HuH-7 and FLC4 cell lines may
ot express the putative HTLV-I receptor(s). Furthermore,
ince human chromosome 17 has been reported to en-
ode a HTLV-I receptor (Gavalchin et al., 1993, 1995;
ommerfelt et al., 1988), we examined the luciferase
ctivity of mouse–human somatic cell hybrids, A9(7151)-3
nd A9(3552)-2 cells containing human chromosomes
7pter–q11: Xq11–qter and 11pter–q23: Xq26–qter, re-
pectively. Irrespective of the incorporation of human
hromosome 17, mouse cell lines exhibited a high de-
ree of luciferase activity. These results suggest that it is
ecessary to identify the cells lacking the HTLV-I recep-
or(s) in order to definitively map its chromosomal local-
zation.
DISCUSSION
HTLV-I is transmitted most efficiently by cell-to-cell
ontact, which leads to the induction of syncytium for-
ation in vitro. Cell-to-cell transmission is considered to
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239HOST RANGE OF HTLV-I BY A NOVEL CELL FUSION ASSAYe at least 100 times more efficient than cell-free trans-
ission (Delamarre et al., 1997; Fan et al., 1992; Landau
t al., 1991; Sommerfelt et al., 1988). Therefore, the syn-
ytium formation assay by cocultivation of HTLV-I-posi-
ive cells with target cells has been widely used to
onitor HTLV-I cell-to-cell transmission in vitro. HTLV-I-
eutralizing epitopes, the role of adhesion molecules
equired for cell-to-cell transmission, such as ICAM-1,
FA-1, and VCAM-1, and members of the transmembrane
superfamily, such as CD82/C33/R2 and CD81/M38/
APA-1, required for syncytium formation have all been
dentified using this assay system (Baba et al., 1993;
ukudome et al., 1992; Furuse et al., 1992; Hildreth et al.,
997; Imai et al., 1992; Imai and Yoshie, 1993; Kuroki et
l., 1992; Palker et al., 1992; Tanaka et al., 1994).
However, this syncytium formation assay remains
omewhat unstable and semiquantitative. The efficiency
f syncytium formation is influenced by lipid composition
nd many other unknown factors other than the specific
nteraction between HTLV-I env glycoproteins and the
utative receptor(s) (Roos et al., 1990). Furthermore,
FIG. 3. Effects of various agents on the cell fusion-dependent reporte
Ab, LAT-27 (B), and synthetic peptide corresponding to aa 400–429 of
onor (A), irrelevant rat IgG (B), and synthetic peptide corresponding t
epresents the mean of at least three independent experiments. Errorince many HTLV-I-infected target cells do not necessar- aly induce syncytium formation, it is difficult to identify
ells that lack the HTLV-I receptor(s) using this syncytium
ormation assay (Delamarre et al., 1997; Rosenberg et al.,
997). To determine the HTLV-I receptor(s), labeled cell-
ree HTLV-I particles and mAbs and synthetic peptides
hat inhibit syncytium formation have been used, and
ome candidates of HTLV-I receptor(s) have been iden-
ified (Agadjanyan et al., 1994; Gavalchin et al., 1993;
ildreth et al., 1997; Krichbaum-Stenger et al., 1987; Sa-
ara et al., 1997, 1998; Siess et al., 1996). However, the
verall research of the HTLV-I receptor(s) has been ham-
ered by the lack of an efficient cell-free transmission
ystem for HTLV-I. Thus, a sensitive and quantitative
ssay system for analyzing HTLV-I env glycoprotein-me-
iated cell fusion is required.
Recently, a quantitative and sensitive assay system for
nalyzing cell fusion by env glycoproteins was devel-
ped by Berger et al. (Nussbaum et al., 1994), who
ucceeded in cloning the chemokine receptor, CXCR-4
fusin), involved in HIV-1-induced membrane fusion by
his system (Feng et al., 1996). Chen et al. also reported
activation. The effects of serum from a HAM patient (A), anti-env gp46
C) were examined at 5 h after cocultivation. The serum from a healthy
2–352 of gp21 (C) were used as negative controls. Each datum point
enote sample standard deviations.r gene
gp21 (
o aa 33sensitive syncytium formation assay by using recom-
b
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240 OKUMA ET AL.inant HTLV-II env glycoprotein and identified a domain
t the amino terminus of the HTLV-II env gp21 responsi-
le for syncytium formation and replication (Li et al.,
996; Poon and Chen, 1998).
In the present study, we established a sensitive and
uantitative assay system in which T7 RNA polymerase
n donor cells coexpressing HTLV-I env glycoproteins
ctivates a reporter gene in recipient cells upon cell
usion. First, several molecules of HTLV-I env glycopro-
eins (mainly 46, 39, and 21 kDa) were detected in the
ells transfected with the expression plasmid by immu-
oblotting (Fig. 1A). Since the molecular mass of env
p46 expressed by using a hybrid-T7 vaccinia system
as reported to range from 39 to 49 kDa due to the
ifferent levels of glycosylation (Arp et al., 1996), the
9-kDa protein detected in this study might thus be a
ariant form (particularly a nonglycosylated form) in the
lycosylation process. Second, the activation of the lu-
iferase gene was inhibited by serum from a HAM pa-
ient, anti-gp46 neutralizing mAb, LAT-27, and synthetic
eptide corresponding to aa 400–429 of gp21, which
ere all shown to inhibit HTLV-I-induced syncytium for-
ation (Fig. 3). These results indicate that the reporter
ene activation detected by this system was specifically
ediated by the HTLV-I env glycoproteins expressed in
he donor cells.
Since anti-gp46 neutralizing mAb LAT-27 recognizes
a 191–196 of gp46, this region seems to be a critical
omain for the binding or interaction with the putative
ellular HTLV-I receptor(s) on target cells in our system.
n fact, a synthetic peptide corresponding to aa 197–208
f gp46 has been reported to inhibit HTLV-I-induced
FIG. 4. An analysis of the pharmacological agents by the reporter
ene activation assay. The effects of heparin, dextran sulfate, and
extran were examined. Each datum point represents the mean of at
east three independent experiments. Error bars denote sample stan-
ard deviations.yncytium formation (Sagara et al., 1996). However, the synthetic peptide corresponding to aa 400–429 of gp21
nhibited cell fusion more efficiently than the peptide
orresponding to aa 197–209 of gp46 in both the syncy-
ium formation assay and the present reporter gene ac-
ivation assay. These results indicate that aa 400–429 of
p21 therefore most likely play an important role in the
iral entry into target cells by membrane fusion after the
ttachment of env gp46 to the HTLV-I receptor(s). Fur-
hermore, the polyanionic compounds, such as dextran
ulfate and heparin, that block cell-to-cell contact inhib-
ted the luciferase activation in a dose-dependent man-
er (Fig. 4). These results suggest that this reporter gene
ctivation assay system could thus be utilized to exam-
ne specific inhibitors for cell fusion mediated by HTLV-I
nv glycoproteins.
The HTLV-I receptor(s) appears to be distributed on
arious cells from several species with the exclusion of
ome mouse, rat, dog, and bovine cell lines. These cells,
ither lacking or expressing a small number of HTLV-I
eceptors, have been reported to include NIH/3T3 (mouse
mbryo), C127:LT (mouse mammary), A9,L-M(TK2) (mouse
onnective tissue), NRK (rat kidney), MDCK (dog kidney),
TABLE 1
Cell Fusion Activity of Various Cell Lines
Cell line Species Propertya
Luciferase activityb
(fold increase)
T-2 Human T(HTLV-I1) 1.4 6 1.8
91/PL Human T(HTLV-I1) 1.2 6 0.9
OLT-4 Human T 3.8 6 1.5
urkat Human T 2.7 6 0.6
audi Human B 13.7 6 11.0
AJI Human B 2.8 6 1.2
-562 Human M 14.4 6 9.5
L60 Human M 3.7 6 4.5
eLa Human E 4.7 6 3.2
93T Human E 2.7 6 0.5
OS Human F 2.8 6 0.6
epG2 Human E 17.7 6 5.1
uH-7 Human E 1.0 6 0.6
LC4 Human E 0.9 6 0.5
C Rat E 8.9 6 6.9
DCK Dog E 5.1 6 2.2
DBK Bovine E 0.6 6 0.3
PK Pig F 3.1 6 1.0
A104 Monkey F 23.0 6 37.8
V-1 Monkey F 7.0 6 2.1
OS-7 Monkey F 2.4 6 1.6
MuLi Mouse E 2.3 6 1.2
IH/3T3 Mouse F 15.6 6 10.2
127:LT Mouse E 9.1 6 5.4
9(7151)-3 Mouse F 16.2 6 6.6
9(3552)-2 Mouse F 10.6 6 5.2
a T, T-cell; B, B-cell; M, myelomonocytoid cell; E, epithelial cell; F,
ibroblastoid cell.
b Fold increase in luciferase activity with Env versus that with Cont.
he results obtained from triplicate samples are given as the means 6
tandard deviations.
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241HOST RANGE OF HTLV-I BY A NOVEL CELL FUSION ASSAYnd MDBK (bovine kidney) (Li et al., 1996; Nagy et al.,
983; Sommerfelt et al., 1988). Reporter gene activation
as detected in cells such as NIH/3T3 and A9, which do
ot show syncytium formation by cocultivation with
TLV-I-positive cells, thus indicating that our assay sys-
em might possibly be more sensitive than the syncytium
ormation assay. By using this system, we found the host
ange of HTLV-I to be broader than expected (Table 1).
TLV-I may utilize a ubiquitous molecule(s) other than
he virus-specific or target-specific proteins as the cel-
ular receptor(s) in the entry of the virus into target cells
nd/or in membrane fusion (Alkhatib et al., 1996; D’Souza
nd Harden, 1996; Deng et al., 1996; Dragic et al., 1996;
eng et al., 1996).
The receptor interference assay indicated the HTLV-I
eceptor to be the same as the HTLV-II receptor (Som-
erfelt and Weiss, 1990). The syncytium formation assay
including a sensitive assay using recombinant vaccinia
irus) (Li et al., 1996; Sommerfelt et al., 1988) and vesic-
lar stomatitis virus pseudotype assay (Sommerfelt et al.,
988) showed the HTLV-I receptor to be encoded by
uman chromosome 17. However, Littman and co-work-
rs indicated the broad host range of HTLV-I by an assay
ystem for pseudotyping using a defective HIV-I genome
n combination with HTLV-I env (Landau et al., 1991;
utton and Littman, 1996) and thus raised a question
egarding the mapping of a HTLV-I receptor to human
hromosome 17, since a high infectivity was detected on
he L-M(TK2) cells. In the present study, we demon-
trated that mouse cell lines exhibited high luciferase
ctivities irrespective of the incorporation of human chro-
osome 17 (Table 1). Recently, the 71-kDa heat shock
ognate protein (HSC70) localized in human chromo-
ome 11 was reported to be a cellular receptor for HTLV-
-induced syncytium formation (Sagara et al., 1998). How-
ver, mAb against HSC70, which was reported to inhibit
TLV-I-induced syncytium formation, did not apparently
nhibit cell fusion either in the syncytium formation assay
sing HTLV-I-positive ILT8M2 and target MOLT-4 cells or
n the present reporter gene activation assay (data not
hown). Thus, further study is necessary to determine an
xact cellular receptor for HTLV-I.
In conclusion, the reporter gene activation method in
hich expression plasmids are transfected as described
n this study revealed that a wide range of cell lines are
usceptible to cell fusion mediated by HTLV-I env glyco-
roteins. To identify the putative cellular HTLV-I recep-
or(s) and to confidently map its chromosomal localiza-
ion, it is therefore necessary to identify cell lines that do
ot have the putative cellular receptor(s). In this context,
he HuH-7 and FLC4 cells may be candidates for cells
acking the cellular HTLV-I receptor(s). The cloning of the
TLV-I receptor gene with these cell lines by using this
eporter gene activation assay system is now under way. pMATERIALS AND METHODS
ells
The HTLV-I-negative MOLT-4 cell line was provided by
. Kannagi (Tokyo Medical and Dental University, Tokyo,
apan) (Kannagi et al., 1991). The HTLV-I-positive C91/PL
ell line was provided by O. Yoshie (Shionogi Institute for
edical Science, Osaka, Japan) (Fukudome et al., 1992;
uruse et al., 1992). The C127:LT cell line was obtained
rom the American Type Culture Collection (Rockville,
D). A9(7151)-3 and A9(3552)-2 cell lines containing hu-
an chromosomes 17pter–q11 Xq11–qter, and 11pter–
23: Xq26–qter, respectively, were obtained from the Hu-
an Science Research Resources Bank (Osaka, Japan).
he HTLV-I-positive cell line MT-2 and the HTLV-I-nega-
ive cell lines Jurkat, RAJI, HL60, K-562, HOS, NIH/3T3,
C, 293T, HepG2, MA104, HuH-7, FLC4, MDBK, MDCK,
PK, CV-1, COS-7, NMuLi, HeLa, and Daudi have been
aintained in our laboratory for a long period. The ad-
erent cell lines were cultured in Dulbecco’s modified
agle’s medium (DMEM, Nissui, Tokyo, Japan) supple-
ented with 10% FCS (Gibco, Gaithersburg, MD), 50
g/ml of streptomycin (Gibco), and 50 units/ml of peni-
illin G (Gibco) in a 5% CO2 incubator at 37°C. The
uspension cell lines were cultured in Daigo’s T medium
Wako Pure Chemical, Osaka, Japan) containing the
ame supplements with DMEM in a 5% CO2 incubator at
7°C.
onstruction of plasmids
pCAGGS vector contains the CAG promoter, which is
omposed of the cytomegalovirus (CMV) immediate
arly enhancer and the chicken b-actin promoter (Niwa
t al., 1991), and has been used for the construction of
xpression plasmids. The T7 RNA polymerase gene was
btained by digestion with BamHI from pAR1173 (Davan-
oo et al., 1984) and ligated into the BglII site of pCAGGS
fter the ligation of the BclI linker, thus resulting in
CAGT7. The HTLV-I env gene was excised with SphI
nd EcoRI from the plasmid, pHAproenv (Shida et al.,
987), and inserted into the BglII site of pCAGGS after
igation of the BclI linker, resulting in pCAGHTLV-I env.
T7EMCLuc containing the 59 untranslated region of
ncephalomyocarditis virus and a firefly luciferase gene
nder the T7 promoter (Aoki et al., submitted for publi-
ation) was used as a reporter plasmid. To normalize the
ransfection efficiency, pRL-CMV vector (Promega, Mad-
son, WI) containing a seapansy luciferase gene under
he CMV promoter was used.
xpression of HTLV-I env and T7 RNA polymerase in
onor cells
The 293T cells (0.75 3 106) were prepared in a 6-well
lat-bottom collagen-coated microplate (Iwaki, Chiba, Ja-
an) and the expression plasmids were transfected by a
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242 OKUMA ET AL.ipofectamine (Gibco) reagent according to the manu-
acturer’s protocol. Briefly, 100 ml of Opti-MEM I Reduced
erum Medium (Gibco), 1 mg of pCAGHTLV-I env, 1 mg of
CAGT7, and 5 ml of the Lipofectamine reagent were
ixed and incubated at room temperature for 15 min.
he mixture was inoculated into the 293T cells preincu-
ated with 0.75 ml of the Opti-MEM I medium. After 3–4
of incubation at 37°C, 1.5 ml of DMEM containing 10%
CS was added to each well and cultured for 36–48 h
ntil cocultivation with the recipient cells.
ransfection of reporter plasmids into recipient cell
ines
For the adherent cells, 5 3 104 cells were prepared for
ransfection in a 96-well flat-bottom collagen-coated mi-
roplate (Iwaki). Five hundred microliters of the Opti-
EM I medium, 25 ml of the Lipofectamine reagent, 5 mg
f pT7EMCLuc, and 0.5 mg of pRL-CMV were mixed and
ncubated at room temperature for 15 min. The mixture
as filled with up to 4.5 ml of Opti-MEM I medium, and
0 ml of the mixture was inoculated into each well con-
aining recipient cells. After being incubated at 37°C for
–4 h, 100 ml of DMEM containing 10% FCS was added
o each well and the cells were cultured at 37°C for
2–18 h until cocultivation with donor cells.
For the suspension cells, 1.4 3 106 cells were washed
nce with phosphate-buffered saline (PBS) and resus-
ended with 2.0 ml of Daigo’s T medium in a 35-mm dish
Becton Dickinson, Mountain View, CA). One hundred
icroliters of the Opti-MEM I medium, 10 ml of SuperFect
ransfection Reagent (Qiagen, Hilden, Germany), 1 mg of
T7EMCLuc, and 0.5 mg of pRL-CMV were mixed and
ncubated at room temperature for 15 min. The mixture
as added to the recipient cells and the cells were then
ncubated at 37°C for 12–18 h until cocultivation with
onor cells.
ell fusion assay
The donor cells cotransfected with pCAGHTLV-I env
nd pCAGT7 were washed once with PBS containing
.05% EDTA and resuspended in DMEM containing 10%
CS. Donor cells (105) in 50 ml of the DMEM were added
o each well of the 96-well microplate in which the same
umber of recipient cells was prepared. After cocultiva-
ion at 37°C for 5 h, the luciferase activities were deter-
ined using the Piccagene Dual Seapansy kit (TOYO
NK, Tokyo, Japan) according to the manufacturer’s pro-
ocol. Briefly, the cocultured cells in each well were lysed
ith 25 ml of lysis buffer by rotating the plate at room
emperature for 30 min. Five microliters of the lysate was
sed to measure the firefly and seapansy luciferase
ctivities by luminometer (Lumat LB 9507, Berthold, Ger-
any). First, the firefly luciferase activity was measured
y adding 25 ml of a firefly luciferase substrate to the
ysate. Next, the seapansy luciferase activity was mea- rured by adding 25 ml of a seapansy luciferase substrate
nto the mixture. The firefly luciferase activity was stan-
ardized by the seapansy luciferase activity as an inter-
al control and the luciferase activity (the standardized
irefly luciferase activity) was expressed as the fold in-
rease compared with each control sample.
mmunoblot analysis
The 293T cells (2 3 106) transfected with the plasmid
n the 6-well microplate were detached with 1 ml of PBS
ontaining 0.05% EDTA. The cell pellet was lysed in 100
l of lysis buffer (10 mM Tris–HCl, pH 7.4, 150 mM NaCl,
mM EDTA, 0.1% SDS, 1% NP-40, 0.1% sodium deoxy-
holate, protease inhibitors containing 10 mg/ml of anti-
ain, elastinal, leupeptin, phosphoramidon, chymostatin,
nd pepstatin A) by incubating at 4°C for 20 min. After
he cell lysates were centrifuged at 18,000 g for 30 min,
0 ml (20 mg protein/lane) of the supernatants was mixed
ith 10 ml of 23 Laemmli’s electrophoresis sample
uffer (0.125 M Tris–HCl, pH 6.8, 20% glycerol, 4% SDS,
% b-mercaptoethanol, 0.012% bromophenol blue) and
pplied for 5–20% gradient sodium dodecyl sulfate–poly-
crylamide gel electrophoresis. The separated proteins
ere then electrophoretically transferred to a nitrocellu-
ose membrane (Amersham, Buckinghamshire, England)
nd the transferred proteins were reacted with serum
rom a HAM patient ( 1
100
dilution). Bound antibodies were
hen reacted with horseradish peroxidase-conjugated
nti-human immunoglobulin (Ig) G (heavy chain specific)
Cappel, West Chester, PA) ( 1
1000
dilution) and were visu-
lized by chemiluminescence and fluorography using an
CL Western immunoblotting kit (Amersham). As a pos-
tive control, 1 3 106 cells of HTLV-I-positive MT-2 cell
ines were lysed in 100 ml of the lysis buffer and 10 ml of
he lysate was used for immunoblotting.
mmunofluorescence analysis
The 293T cells transfected with the plasmid were
ashed once with PBS containing 1% BSA and 0.1%
aN3 (PBS–BSA) and then were fixed with PBS contain-
ng 4% paraformaldehyde at room temperature for 2 h.
fter being washed once with PBS–BSA, the cells were
ncubated at room temperature for 30 min with PBS–BSA
ontaining serum from a HAM patient ( 1
100
dilution). After
eing washed twice with PBS–BSA, the cells were incu-
ated at room temperature for 30 min with PBS–BSA
ontaining fluorescein isothiocyanate-conjugated goat
nti-human IgG (Cappel) ( 1
100
dilution). After being
ashed twice with PBS–BSA, the cells were observed
nder a fluorescence microscope (Carl Zeiss, Germany).
iscellaneous reagents
The sera were collected from HAM patients and
ealthy donors. The anti-HTLV-I env gp46 mAb (LAT-27,at IgG), which recognizes aa 191–196 of gp46 and has
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243HOST RANGE OF HTLV-I BY A NOVEL CELL FUSION ASSAYhe neutralizing activity of HTLV-I infection, was provided
y Y. Tanaka (Kitasato University, Kanagawa, Japan). Syn-
hetic peptides corresponding to aa 197–209 of env gp46
nd aa 332–352 and 400–429 of gp21 were synthesized
sing a previously described method (Baba et al., 1993,
995; Kuroki et al., 1992). The purity of these peptides
as greater than 95% as determined by a high-
erformance liquid chromatography analysis. Heparin
sodium salt), dextran sulfate [sodium salt, molecular
eight (MW) 8000], and dextran (MW 10,000) were pur-
hased from the Sigma Chemical Co. (St. Louis, MO).
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